SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Severance and Change in Control Agreement (the “Agreement”) is entered into as of November 29, 2022 (the “Effective Date”) by and between Jeffrey M. Goldberg (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (together with its subsidiaries, the “Company”).
SEVERANCE AGREEMENTSeverance Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Severance Agreement (the "Agreement") is entered into as of October 21, 2019 (the "Effective Date") by and between Michael Hanley (the "Executive") and Aeglea BioTherapeutics, Inc., a Delaware corporation (the "Company").
August 24, 2022Consulting Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter confirms the agreement (“Agreement”) between you and Aeglea BioTherapeutics, Inc. (the “Company”) concerning the terms of your transition and resignation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and covenant not to sue now and upon the termination of your consultancy. If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.
